The collaboration will focus on the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy
Fluidigm COVID-19 campus safeguard program improves availability of non-invasive, saliva-based SARS-CoV-2 tests for higher education institutions
Exclusive interviews, new methods, free downloads and more to help advance your pharma and biopharma research & development
CE mark for MitraClip G4 offers physicians an innovative next-generation system with more options for mitral valve repair using proven clip-based technology
Promega and Incyte intend to work together in the future to develop the Promega OncoMate MSI Assay as a companion diagnostic
The Proxima spatial analysis software solution integrates image acquisition to data analysis in the secure cloud for rapid access by any user
The new line aims to provide unmatched sensitivity, resolution, speed, and flexibility of colors
Emergency scans captured images of the top of the lungs where a fluffiness known as ‘ground glass opacification’ allowed COVID-19 to be diagnosed
AstraZeneca anticipates entering clinical development in 2021
The technology is said to be superior at identifying cell types in human blood, providing faster and more reliable assessments for clinical decision making
The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus
The partnership aims to co-market exosome technology as well as the joint development of new exosome based products
New test expands Roche molecular test menu for transplant patients, enabling simultaneous testing of BK virus with Cytomegalovirus and Epstein-Barr virus
Data shows 100% concordance with results from Dartmouth-Hitchcock’s lab-based polymerase chain reaction (PCR) test method
The overall goal is to continue to detect and discover critical components in the overall cellular response to COVID-19
The kits aim to detect traces of SARS-CoV-2 virus on surfaces such as plastics, ceramics and stainless steel
IgM assay has 95.51% positive predictive value even when disease incidence is only 3%
The new assays are designed to enable turnaround times for next-generation sequencing results of less than 24 hours
Nirsevimab is the first potential passive immunisation for infants to demonstrate sustained protection across the entire RSV season with a single dose
The partnership enables LUMICKS to expand on the implementation of the z-Movi to new immunotherapeutic settings
This powerful new solution aims to provide more accurate COVID-19 antibody detection
Just leave a quick lab product review today for your chance to scoop one of our weekly $100 prizes
The modular solution aims to deliver test results in a four-step process requiring minimal hands-on time, laboratory space and staffing resources
Exclusive interviews, new methods, free downloads, and much more to help you advance your work
